Programa De Salud En El Hogar Y Hospicio Geminis Carretera 159 Km 13,4 Urb Loma Linda, Corozal, PR, 00783 | |
(787) 859-5755 |
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.
According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
› Verified 5 days ago
Name | Programa De Salud En El Hogar Y Hospicio Geminis |
---|---|
Location | Carretera 159 Km 13,4 Urb Loma Linda, Corozal, Puerto Rico |
Hospice ID | 401563 |
Category | Freestanding Hospice |
Ownership Type | Voluntary Non-profit - Private |
Profit Type | NON-PROFIT |
Accreditation Provider | The Joint Commission (TJC) |
SSA county code | 230 |
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.
According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
› Verified 5 days ago
NPI Number | 1235217852 |
Organization Name | Programa De Servicios De Salud En El Hogar Geminis Inc |
Address | Carr.159 Km 13.4 (bo Pueblo) Corozal, Puerto Rico, 00783 |
Phone Number | (787)859-5755 |
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.
According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
› Verified 5 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.
According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
› Verified 5 days ago
Home Health Aides | 0.5 |
Counselors | 1 |
Homemakers | 8 |
Licensed Practical or Vocational Nurses | 0.5 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 4 |
Total Employees | 16 |
---|
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.
According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
› Verified 5 days ago
Others | 9 |
Total Volunteers | 9 |
---|
News Archive
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis' oncolytic agent, Eloxatin®.
According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
› Verified 5 days ago
Programa De Salud En El Hogar Y Hospicio Geminis Location: Carretera 159 Km 13,4 Urb Loma Linda, Corozal, Puerto Rico, 00783 Phone: (787) 859-5755 |